Dimensional Fund Advisors LP decreased its holdings in Cutera, Inc. (NASDAQ:CUTR) by 20.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 693,366 shares of the medical device company’s stock after selling 173,976 shares during the quarter. Dimensional Fund Advisors LP owned approximately 5.00% of Cutera worth $17,958,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also modified their holdings of CUTR. Morgan Stanley increased its stake in shares of Cutera by 23.3% in the 1st quarter. Morgan Stanley now owns 67,345 shares of the medical device company’s stock valued at $1,395,000 after buying an additional 12,734 shares during the period. Teachers Advisors LLC increased its stake in shares of Cutera by 50.7% in the 2nd quarter. Teachers Advisors LLC now owns 62,702 shares of the medical device company’s stock valued at $1,624,000 after buying an additional 21,088 shares during the period. Kennedy Capital Management Inc. acquired a new stake in shares of Cutera in the 2nd quarter valued at $9,426,000. Scout Investments Inc. acquired a new stake in shares of Cutera in the 2nd quarter valued at $1,454,000. Finally, Renaissance Technologies LLC increased its stake in shares of Cutera by 0.8% in the 2nd quarter. Renaissance Technologies LLC now owns 1,214,500 shares of the medical device company’s stock valued at $31,456,000 after buying an additional 9,100 shares during the period. Hedge funds and other institutional investors own 88.72% of the company’s stock.
CUTR has been the subject of several research reports. BidaskClub cut Cutera from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Roth Capital lifted their target price on Cutera from $32.00 to $39.00 and gave the company a “buy” rating in a research note on Tuesday, August 8th. Gabelli reissued a “buy” rating on shares of Cutera in a research note on Wednesday, August 9th. TheStreet raised Cutera from a “c” rating to a “b” rating in a research note on Friday, August 18th. Finally, Maxim Group cut Cutera from a “buy” rating to a “hold” rating in a research note on Thursday, September 14th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $37.33.
In related news, Director David B. Apfelberg sold 1,000 shares of Cutera stock in a transaction on Monday, September 18th. The stock was sold at an average price of $38.45, for a total transaction of $38,450.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Larry Laber sold 1,700 shares of Cutera stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $42.15, for a total value of $71,655.00. Following the sale, the executive vice president now directly owns 72,413 shares of the company’s stock, valued at $3,052,207.95. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 68,009 shares of company stock valued at $2,438,915. 11.60% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: This news story was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://stocknewstimes.com/2017/11/11/cutera-inc-cutr-shares-sold-by-dimensional-fund-advisors-lp.html.
Shares of Cutera, Inc. (CUTR) opened at $42.45 on Friday. Cutera, Inc. has a 52 week low of $13.70 and a 52 week high of $44.40. The company has a market capitalization of $576.37, a price-to-earnings ratio of 53.33, a P/E/G ratio of 1.73 and a beta of 0.49.
Cutera (NASDAQ:CUTR) last announced its quarterly earnings data on Tuesday, November 7th. The medical device company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.34. Cutera had a return on equity of 18.73% and a net margin of 7.99%. The business had revenue of $38.17 million during the quarter, compared to analysts’ expectations of $34.82 million. During the same period in the previous year, the firm earned $0.12 earnings per share. The firm’s quarterly revenue was up 26.1% compared to the same quarter last year. equities research analysts predict that Cutera, Inc. will post 0.55 EPS for the current fiscal year.
Cutera declared that its board has initiated a share repurchase plan on Monday, August 7th that allows the company to repurchase $25.00 million in shares. This repurchase authorization allows the medical device company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s management believes its shares are undervalued.
Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.
Receive News & Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related companies with MarketBeat.com's FREE daily email newsletter.